Created at Source Raw Value Validated value
Dec. 5, 2020, 12:45 a.m. oms

1) Patients who had been already treated with ceratain drug for COVID-192) Patients diagnosed with relapse or 2nd infection of COVID-193) Patiens with obvious other respiratory infection 4) Patients having cardiac dysfunctions such as congestive heart failure5) Patients having severe liver dysfunction such as Child-Pugh C state6) Patients having renal dysfunction requiring dialysis7) Patients having immuno deficiency such as HIV infection8) Patients having disorders of consciousness such as disorientation9) Patients using the drug of immuno suppression10) Patients using steroid inhaler11) Patients who are pregnant or who may be pregnant12) Patients who cannot use contraceptive 13) Male patients having a partner who agree with the usage of contraceptive 14) Patients with hereditary xanthineuria15) Patients with Patients with hypouricemia or xanthine urinary stone 16) Patients with retractable gout or hyperuricemia17) Patents with allergy of favipiravir, camostat mesilate or inhaled ciclesonide18) Patients in severe disease state with artificial ventilation, or ECMO in intensive care unit19) Patients who are considered inappropriate for inclusion in the study by the investigator

1) Patients who had been already treated with ceratain drug for COVID-192) Patients diagnosed with relapse or 2nd infection of COVID-193) Patiens with obvious other respiratory infection 4) Patients having cardiac dysfunctions such as congestive heart failure5) Patients having severe liver dysfunction such as Child-Pugh C state6) Patients having renal dysfunction requiring dialysis7) Patients having immuno deficiency such as HIV infection8) Patients having disorders of consciousness such as disorientation9) Patients using the drug of immuno suppression10) Patients using steroid inhaler11) Patients who are pregnant or who may be pregnant12) Patients who cannot use contraceptive 13) Male patients having a partner who agree with the usage of contraceptive 14) Patients with hereditary xanthineuria15) Patients with Patients with hypouricemia or xanthine urinary stone 16) Patients with retractable gout or hyperuricemia17) Patents with allergy of favipiravir, camostat mesilate or inhaled ciclesonide18) Patients in severe disease state with artificial ventilation, or ECMO in intensive care unit19) Patients who are considered inappropriate for inclusion in the study by the investigator